logo
Experts Say This Common Hobby Will Boost Brain Power At Any Age. Here's Why.

Experts Say This Common Hobby Will Boost Brain Power At Any Age. Here's Why.

Yahoo23-07-2025
A new study found that playing an instrument could be super beneficial for your brain health.
The results suggest the brain processes of older folks who play instruments actually act similar to those seen in younger people.
Two doctors break down the study and what it means for you. Hint: It's never too late!
If eating whole foods, getting good sleep, regular exercise are already in rotation in your longevity arsenal, consider taking up a new instrument.
Research that was recently published in the journal PLOS Biology found that the brains of older musicians actually work a lot like younger people's brains. So, should you pull out your dusty old recorder from elementary school to reap all those longevity benefits? Well, neurologists say there's definitely credence to the link between music and good brain health as you age. Here's why that is.
Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University.
What did the study find?
The study, which was published in PLOS Biology, studied the brains of 74 people with functional magnetic resonance imaging (fMRI) to measure their brain activity. Some of the participants were older musicians, others were older folks who didn't play an instrument, and the rest were young non-musicians. Each was asked to identify syllables that were masked by sounds, mimicking a noisy environment. (Why? Well, as we get older, it's usually harder to perceive and process information, including hearing things in loud areas.)
The researchers discovered that the brains of older musicians were better able to process speech in the noisy situations compared to older non-musicians. Specifically, their brains mimicked those of younger non-musicians in how they perceived noise.
The researchers concluded that people who played instruments had more 'cognitive reserve' that allowed them to better process sounds in a noisy environment.
Why is playing an instrument associated with better brain health?
The answer to this is not entirely clear. 'In general, advanced education is associated with a diminished risk of decline with memory later in life,' says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University. 'We do know that to learn new languages and skills, robust new connections between brain regions must be established. We think that this density of connections help make a brain resilient.'
It also takes a lot of brain power to create songs, points out Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica. 'The processes in the brain that allow musicians to make music with mixed harmonies, rhythms, and sounds is complex and requires multiple brain region activations to do,' he says. By regularly flexing that skill, you ultimately build up a stronger brain, he explains.
If I don't play an instrument, is it too late to start?
Nope. Neurologists say you can pick up an instrument any time and still reap the benefits. 'It is never too late to start playing an instrument or singing if we are talking about brain health,' Dr. Segil says. 'The ability to translate a sheet of music into something requires activation of the visual parts or your brain, the auditory parts of the brain, and the association areas of your brain. These can be trained at age 13 or 73 and are healthy your brain at either age.'
By the way, Dr. Segil says you don't have to be Taylor Swift or Beyonce to make this flex work for you. "The beautiful brain health reality is playing out of tune or off still will likely increase brain functional connectivity," he says. "Your brain won't know if you are carrying the tune well or bad and will still benefit from making music."
What are the other cognitive benefits of playing an instrument?
There are actually a ton of cognitive benefits to playing an instrument that go well beyond the longevity-related ones. 'Playing an instrument requires eye hand coordination, eye and ear coordination, and higher processing when adding rhythms to this process,' Dr. Segil says. This means that multiple parts of your brain need to be activated at once to make music—and that's healthy for your brain, he says.
Plus, the ability to read music is similar to the ability to read in another language, per Dr. Segil, and reading music or a second language "requires different brain pathway activation than reading in your primary language and therefore is good for brain health.'
But of course, Dr. Sachdev warns that you shouldn't force yourself to learn to play an instrument if it's not your thing. 'The most important thing to remember is that you want to pursue it to support your mental health and wellness,' he says. 'It needs to be fun.' Dr. Sachdev points out that you can also just do your brain a solid by socializing with people. And if you happen to do a hobby together with them, even better. 'Pursue your passions, new or old, with a group of like-minded folks,' he says.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs

Fast Company

time16 minutes ago

  • Fast Company

Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters

Optimizing Therapies for HR+ Early-Stage Breast Cancer
Optimizing Therapies for HR+ Early-Stage Breast Cancer

Medscape

time16 minutes ago

  • Medscape

Optimizing Therapies for HR+ Early-Stage Breast Cancer

Hormone receptor-positive (HR+) early-stage breast cancer is one of the most common types of breast cancer, characterized by tumor cells that have receptors for estrogen or progesterone hormones. Although significant progress has been made in screening, treatment, and surgery, the risk of recurrence still remains. To explore therapies for managing HR+ early-stage breast cancer, Medscape spoke with Hope S. Rugo, MD, FASCO, division chief of breast medical oncology and a professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center, Duarte, California, and professor emeritus at the University of California San Francisco. Read on for her insights. What role does risk stratification play in determining therapy for HR+ early-stage breast cancer? Hope S. Rugo, MD, FASCO This is a critical area. It is a key aspect of determining appropriate treatment and extent of treatment, and we are still learning more about how to appropriately stratify based on clinicopathologic and genomic characteristics. Gene expression tests are used widely to understand prognosis and benefit from chemotherapy, but there are ongoing issues in HR+ disease including disease heterogeneity and how to optimally treat very young women with HR+ disease. We use clinicopathologic data in combination with gene expression tests to stratify risk, but this approach doesn't always provide us with the necessary information for determining the optimal adjuvant or neoadjuvant treatment. The adjuvant CDK4/6 inhibitor trials will be helpful, as they will allow for longer follow-up of patients with high- and intermediate-risk disease. Additionally, newer predictors, such as gene expression signatures that may estimate the benefit from immunotherapy, are also being evaluated. What factors influence your choice between endocrine therapy and chemotherapy for HR+ early-stage breast cancer? Multiple factors have an influence on the choice of therapy, including the extent of disease and tumor biology. We have also learned that the intensity or extent of estrogen positivity plays a role in endocrine sensitivity. In terms of tumor biology, understanding tumor proliferation and chemotherapy sensitivity is critical. We are currently using gene expression tests, but it is clear that these are insufficient, even within the context of age and tumor burden. Additional markers that help to identify up-front or emerging resistance to endocrine therapy are critical. Data from the CDK4/6 inhibitor adjuvant trials has further complicated this question — as now the issue is where optimal outcome can be achieved in less chemotherapy-responsive, higher-risk disease with the addition of abemaciclib or ribociclib. Considering recent research, is extended endocrine therapy actually beneficial? I believe it is, but careful consideration needs to be given to the decision to extend therapy. Disease burden is of course our first consideration, but sensitivity to endocrine therapy, development of resistance, and response to chemotherapy in appropriate cases need to be taken into consideration. Interestingly, several analyses have suggested that patients with low proliferative and genomic risk, but a higher disease burden, might be most likely to benefit from extended duration endocrine therapy due to the long natural history of this disease. We are now exploring the use of switching the type of endocrine therapy in the high-risk adjuvant setting and the use of circulating tumor DNA (ctDNA) to optimize therapy. What role do CDK4/6 inhibitors play in the adjuvant setting for HR+ early-stage disease? Both abemaciclib and ribociclib have reduced the risk of recurrence and the risk of distant recurrence in patients with intermediate or high-risk early-stage breast cancer. The duration of therapy varies, and eligibility criteria overlap; however, the recent NATALEE trial included a diverse population, including an intermediate-risk group (stage II, node-negative with additional risk factors) to evaluate the role of the CDK4/6 inhibitors among such populations. The striking aspect of this trial was the carry-over effect, shown most clearly in the monarchE study with 5-year follow-up. Even 3 years after completing treatment with abemaciclib, the data showed an increasing impact on disease-free survival and distant disease-free survival. Although there has been no overall survival impact yet, fewer patients with abemaciclib in monarchE are living with metastatic disease. What are the most critical research gaps or upcoming trials that could reshape how we manage HR+ early-stage breast cancer in the upcoming years? A few main things to address are improving risk stratification, how to use ctDNA to improve outcome, and understanding if use of oral selective estrogen receptor degrader (SERDs) in sequence improve outcome and their optimal therapy duration. So far, studies using ctDNA to assess risk and guide therapy changes have been challenging due to the low number of positive ctDNA results. Moreover, ctDNA detection has sometimes coincided with metastatic disease already visible on scans in case of several aggressive cancers. We still don't know the optimal treatment approach when molecular evidence of disease is found, which is making studies focus on adding targeted therapy or changing endocrine therapy. Several trials are evaluating oral SERDs in the early stage setting for the treatment of high-risk disease. While these trials will also collect ctDNA, patient eligibility is not based on these tests. One very important area that requires additional research is understanding early-stage breast cancer in young women, where tumors seem to behave poorly — particularly in women under the age of 40 — even when patients are treated with optimal therapy. Understanding optimal therapy is a key research focus, and further investigation of biological drivers in both ductal and lobular cancers is warranted. The OFFSET trial aims to determine the value of adjuvant chemotherapy vs ovarian function suppression in conjunction with standard endocrine therapy and CDK4/6 inhibitors as indicated. However, this study is challenging to enroll in. Hope S. Rugo, MD, FASCO, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Chugai; Puma; Sanofi; Napo; Mylan Received research grant from: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics; OBI Pharma; Ambrx

Cowboys' Jerry Jones reveals scary skin cancer battle
Cowboys' Jerry Jones reveals scary skin cancer battle

Fox News

time17 minutes ago

  • Fox News

Cowboys' Jerry Jones reveals scary skin cancer battle

Dallas Cowboys team owner Jerry Jones revealed he overcame an off-the-field battle as he holds out hope that the organization he helped make one of the most valuable in sports reaches the Super Bowl once more. Jones revealed in an interview with the Dallas Morning News that he was diagnosed with stage 4 melanoma skin cancer in June 2010 and started his treatment soon after. The report noted that Jones slightly touched on undergoing cancer treatments a "dozen years ago" during one of the episodes of the Netflix docuseries "America's Team: The Gambler and His Cowboys." "I was saved by a fabulous treatment and great doctors and a real miracle (drug) called PD-1 (therapy)," he told the Morning News. "I went into trials for that PD-1 and it has been one of the great medicines. "I now have no tumors." Jones said he's had four surgeries over the last 10 years – two on his lungs and two to deal with his lymph nodes. Melanoma is a less common form of skin cancer that is more dangerous than other varieties because it's much more likely to spread to other parts of the body if not found and treated early, according to the American Cancer Society. The Melanoma Research Alliance said stage 4 means the cancer "metastasized (spread) to other places throughout the body, such as the brain, lungs, liver, or gastrointestinal (GI) tract." "The 5-year survival rate as of 2018 for distant metastatic (Stage IV) melanoma is 22.5%," the research organization stated on its website. Jones, 82, is set to embark on another NFL season as the head of the Cowboys. Sportico revealed its NFL valuations on Wednesday with the Cowboys leading the league at $12.8 billion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store